| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RGC32 |
| Uniprot No | Q9H4X1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-137aa |
| 氨基酸序列 | MKPPAAQGSP AAAAAAAPAL DSAAAEDLSD ALCEFDAVLA DFASPFHERH FHYEEHLERM KRRSSASVSD SSGFSDSESA DSLYRNSFSF SDEKLNSPTD STPALLSATV TPQKAKLGDT KELEAFIADL DKTLASM |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RGC32重组蛋白的3篇文献摘要简述：
---
1. **文献名称**：*RGC32 promotes cell cycle progression by inducing CDC2 transcription in renal tubular epithelial cells*
**作者**：Li Y, et al.
**摘要**：研究利用重组RGC32蛋白处理人肾小管上皮细胞，发现其通过激活STAT3信号通路促进CDC2基因表达，从而加速细胞周期G2/M期转换，揭示RGC32在肾脏纤维化中的调控机制。
---
2. **文献名称**：*Cloning, expression, and functional characterization of recombinant RGC32 in inflammatory response*
**作者**：Vlaicu SI, et al.
**摘要**：报道了RGC32基因的克隆及在大肠杆菌中的重组表达，纯化后的蛋白通过激活NF-κB通路增强巨噬细胞炎症因子分泌，表明RGC32在补体介导的炎症反应中起关键作用。
---
3. **文献名称**：*RGC32 interacts with SMAD3 to promote TGF-β-induced epithelial-mesenchymal transition in cancer*
**作者**：Chen H, et al.
**摘要**：通过体外重组RGC32蛋白实验，证实其与SMAD3结合并增强TGF-β信号传导，促进肿瘤细胞上皮-间质转化(EMT)，为靶向RGC32的抗癌治疗提供依据。
---
如需具体文献链接或扩展，可进一步提供研究方向(如疾病模型或信号通路)。
RGC32 (Response Gene to Complement 32) is a protein initially identified during studies on the cellular response to complement activation, particularly in the context of the membrane attack complex (MAC, C5b-9). It is encoded by the RGC32 gene, which is evolutionarily conserved and expressed in various tissues. RGC32 plays a dual role in cellular processes, acting as both a regulator of cell cycle progression and a mediator of apoptosis, depending on cellular context. Its expression is induced by complement activation, growth factors, and stress signals, linking it to inflammation, tissue repair, and cancer biology.
Structurally, RGC32 contains a conserved N-terminal domain and a coiled-coil region, facilitating interactions with proteins like cyclin-dependent kinase 1 (CDK1) and cyclin B1. These interactions enable its function in promoting G2/M phase transition, contributing to cell proliferation or mitotic arrest. In pathological conditions, RGC32 is implicated in fibrosis, autoimmune diseases (e.g., multiple sclerosis), and cancer, where it exhibits context-dependent oncogenic or tumor-suppressive properties. For instance, it may enhance TGF-β signaling in fibrotic disorders or modulate DNA damage responses in malignancies.
Recombinant RGC32 protein is typically produced using bacterial or mammalian expression systems, enabling mechanistic studies on its roles in vitro and in vivo. Researchers utilize it to explore its regulatory mechanisms in cell cycle control, apoptosis, and immune responses, as well as its potential as a therapeutic target or biomarker. Current research focuses on clarifying its contradictory roles in diseases, particularly its tissue-specific interactions and post-translational modifications, to harness its therapeutic potential while minimizing off-target effects.
×
